LA JOLLA, Calif., Feb. 10, 2014 /PRNewswire/ -- Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced the completion of its initial public offering of 8,050,000 shares of its common stock at an initial public offering price of $12.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,050,000 additional shares of common stock. Auspex's common stock is listed on the NASDAQ Global Market under the trading symbol "ASPX." Auspex expects to use the net proceeds from the offering primarily for the clinical development and commercialization of SD-809, as well as for general corporate purposes.
The joint book-running managers for the offering were Stifel and BMO Capital Markets. In addition, Robert W. Baird & Co. Incorporated, William Blair and Company, L.L.C. and Ladenburg Thalmann & Co. Inc. acted as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 4, 2014. The offering was made by means of a prospectus, copies of which may be obtained from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Attention: Syndicate, by telephone at (415) 364-2720 or by email to SyndicateOps@stifel.com, or from BMO Capital Markets Corp., 3 Times Square, 27th Floor, New York, NY 10036, Attention: Equity Syndicate Department, by telephone at (800) 414-3627 or by email to firstname.lastname@example.org.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Auspex Pharmaceuticals Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. Auspex's pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington's disease, tardive dyskinesia and Tourette syndrome, as well as other orphan indications. Auspex's lead product candidate, SD-809, is in a Phase 3 registration clinical trial for the treatment of chorea (abnormal involuntary movements) associated with Huntington's disease. Auspex has employed its deuterium chemistry approach to optimize other deuterium-containing compounds in its portfolio that are at various stages of development. For further information, please visit the company's website www.auspexpharma.com.
SOURCE Auspex Pharmaceuticals